TALLC

What TALLC does

TALLC is a private, early-stage pharmaceutical manufacturer headquartered in Laval, Canada, founded in 2020 and operating with a team of 11-50 employees. According to its self-description, the company produces medicines across four therapeutic and technology areas: ophthalmology, surgical pain management, inflammation, and nanotechnology-enabled drug delivery. The breadth of these focus areas relative to the company's small headcount suggests either an early pipeline with multiple candidates, a formulation platform play, or positioning ahead of disclosed commercial activity. The entity is led by Chief Executive Officer Damon Smith, and its corporate website at tallcinc.com is publicly accessible.

No additional operating details are disclosed in the source material: there is no information on specific products, approved drug master files, manufacturing certifications, GMP status, pipeline stage, clinical milestones, customer contracts, channel partners, pricing, or revenue. Ownership, investor base, funding history, geographic markets served, and any M&A or partnership activity are likewise undocumented. As a result, TALLC should be treated as a thinly disclosed specialty pharma entity at an early stage of corporate development, where the verifiable surface area is limited to its founding, location, leadership, headcount band, and stated therapeutic focus.

Name

TALLC

Website

https://tallcinc.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

TALLC is a private Canadian pharmaceutical manufacturer founded in 2020, based in Laval, that produces medicines in ophthalmology, surgical pain, inflammation, and nanotechnology-enabled drug delivery, operating with a small early-stage team.

Ownership category

akta.pro rank

Headquarters

HQ city

Laval

HQ country

Canada

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales

Core offering

TALLC is a pharmaceutical manufacturing company that produces medicines for ophthalmology, surgical pains, inflammation, and nanotechnology-based therapeutics. The company operates a small-scale (11–50 employees) specialty pharma production capability out of Laval, Canada. No individual branded product names are disclosed in the available source material.

Product overview

No product information available in the provided source data.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights2 records

Direct peers

• Cambrex: Contract manufacturer of active pharmaceutical ingredients and finished dosage forms serving small and large pharma. Direct comparable for a specialty pharma manufacturer operating across multiple therapeutic areas.
• Hovione: Contract pharmaceutical development and manufacturing organization with deep capability in complex formulations, including nanotechnology-enabled drug delivery. Closely comparable to TALLC's stated pharma manufacturing and nanotech focus.
• Kala Bio: Clinical-stage biopharma developing ophthalmic therapies using a proprietary nanoparticle mucus-penetrating particle technology. Highly comparable given TALLC's explicit ophthalmology and nanotechnology positioning.
• Ocular Therapeutix: Specialty ophthalmology pharma with sustained-release drug delivery platforms for eye conditions. Closely comparable as a specialty ophthalmology pharma pursuing delivery innovation.
• Catalent: Global contract development and manufacturing organization serving pharma and biotech across multiple dosage forms and therapeutic areas including ophthalmology. Directly comparable business model to TALLC's specialty pharma manufacturing.

Broad incumbents

• AbbVie (Allergan): Major pharma with significant ophthalmology and pain/inflammation portfolios inherited from Allergan. Broad incumbent competing in TALLC's target therapeutic verticals.
• Bausch Health (Bausch + Lomb): Global pharmaceutical and ophthalmology company with established franchises in eye health, surgical, and inflammation. A broad incumbent whose core therapeutic areas overlap directly with TALLC's stated focus.
• Patheon (Thermo Fisher Scientific): Large-scale contract pharma manufacturer and development services provider within Thermo Fisher. Comparable business model with substantially broader scale and resources.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

• Xx.com/TallcInc

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TALLC